1563176-59-9

Basic information

• Product Name: 5,6-trans Travoprost
• Synonyms: 5,6-trans Travoprost;(5E)-7-[(1R,3R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxy-4-[3-(trifluoroMethyl)phenoxy]-1-buten-1-yl]cyclopentyl]-5-heptenoic Acid 1-Methylethyl Ester;(5E)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-buten-1-yl]cyclopentyl]-5-heptenoic acid 1-methylethyl ester;MKPLKVHSHYCHOC-JPVYXPJZSA-N
• CAS NO: 1563176-59-9
• Molecular Formula: C26H35F3O6
• Molecular Weight: 500.5477096
• Product Categories: Agonists;Chiral Reagents;Impurities;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 1563176-59-9.mol
• Article Data: 23

Chemical Properties

• Boiling Point: 584.8±50.0 °C(Predicted)
• Appearance: /
• Density: 1.245±0.06 g/cm3(Predicted)
• Storage Temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• Solubility: Chloroform (Slightly), Dichloromethane (Slightly), Methanol (Slightly)
• PKA: 13.43±0.20(Predicted)
• CAS DataBase Reference: 5,6-trans Travoprost(CAS DataBase Reference)
• NIST Chemistry Reference: 5,6-trans Travoprost(1563176-59-9)
• EPA Substance Registry System: 5,6-trans Travoprost(1563176-59-9)

Safety Data

• Hazardous Substances Data: 1563176-59-9(Hazardous Substances Data)

Usage

Description

5,6-trans Travoprost is an isomeric impurity of the selective FP prostaglandin receptor agonist Travoprost (T715600). It is a chemical compound derived from the parent compound Travoprost, which is primarily used in the treatment of glaucoma and ocular hypertension.

Uses

Used in Pharmaceutical Industry:
5,6-trans Travoprost is used as an isomeric impurity for the selective FP prostaglandin receptor agonist Travoprost. The presence of this impurity in the final product can affect the efficacy, safety, and quality of the medication. It is essential to monitor and control the levels of 5,6-trans Travoprost during the manufacturing process to ensure the desired therapeutic outcomes and minimize potential side effects.
Application Reason:
The use of 5,6-trans Travoprost as an isomeric impurity in the pharmaceutical industry is crucial for maintaining the quality and efficacy of Travoprost-based medications. By controlling the levels of this impurity, manufacturers can ensure that the final product meets the required standards for safety and effectiveness in treating glaucoma and ocular hypertension. Additionally, understanding the properties and effects of 5,6-trans Travoprost can help researchers develop new therapeutic strategies and improve existing treatments for these eye conditions.

Upstream product

• 98-17-9 3-Trifluoromethylphenol 
• 336625-17-3 dimethyl [3-(2-iodo-5-trifluoromethyl-phenoxy)-2-oxo-propyl]-phosphonate 
• 67-63-0 isopropyl alcohol 
• 54276-17-4 (+)-fluprostenol 
• 208180-17-0 (3aR,4R,5R,6aS)-5-((tetrahydro-2H-pyran-2-yl)oxy)-4-((3R,E)-3-((tetrahydro-2H-pyran-2-yl)oxy)-4-(3-(trifluoromethyl)phenoxy)but-1-en-1-yl)hexahydro-2H-cyclopenta[b]furan-2-one 
• 31752-99-5 (-)-Corey lactone 5-(4-phenylbenzoate) 
• 38754-71-1 (3aR,4R,5R,6aS)-4-formyl-2-oxohexahydro-2H-cyclopenta[b]furan-5-yl biphenyl-4-carboxylate 
• 336625-22-0 [1R-[1α(Z),2β(1E,3R*),3α,5α]]-7-[3,5-dihydroxy-2-[3-hydroxy-4-[2-iodo-5-(trifluoromethyl)phenoxy]-1-butenyl]cyclopentyl]-5-heptenoic acid 1-methylethyl ester 
• 102771-00-6 2-iodo-5-(trifluoromethyl)phenol 
• 336625-15-1 ethyl (2-iodo-5-trifluoromethyl-phenoxy)acetate 
• 336625-21-9 (3aR)(3aα,4β,5α,6aα)-5-hydroxy-4-[(E)-3-hydroxy-4-(2-iodo-5-trifluoromethylphenoxy)-but-1-enyl]-hexahydro-cyclopenta[b]furan-2-one 
• 336625-19-5 Benzoic acid (3aR,4R,5R,6aS)-4-[(E)-4-(2-iodo-5-trifluoromethyl-phenoxy)-3-oxo-but-1-enyl]-2-oxo-hexahydro-cyclopenta[b]furan-5-yl ester 
• 336625-20-8 Benzoic acid (3aR,4R,5R,6aS)-4-[(E)-3-hydroxy-4-(2-iodo-5-trifluoromethyl-phenoxy)-but-1-enyl]-2-oxo-hexahydro-cyclopenta[b]furan-5-yl ester 
• 337529-28-9 (3aR,4R,5R,6aS)-4-[(E)-4-(2-Iodo-5-trifluoromethyl-phenoxy)-3-(tetrahydro-pyran-2-yloxy)-but-1-enyl]-5-(tetrahydro-pyran-2-yloxy)-hexahydro-cyclopenta[b]furan-2-one 

Relevant articles and documents

Concise, scalable and enantioselective total synthesis of prostaglandins

Prostaglandins are among the most important natural isolates owing to their broad range of bioactivities and unique structures. However, current methods for the synthesis of prostaglandins suffer from low yields and lengthy steps. Here, we report a practicability-oriented synthetic strategy for the enantioselective and divergent synthesis of prostaglandins. In this approach, the multiply substituted five-membered rings in prostaglandins were constructed via the key enyne cycloisomerization with excellent selectivity (>20:1 d.r., 98% e.e.). The crucial chiral centre on the scaffold of the prostaglandins was installed using the asymmetric hydrogenation method (up to 98% yield and 98% e.e.). From our versatile common intermediates, a series of prostaglandins and related drugs could be produced in two steps, and fluprostenol could be prepared on a 20-gram scale. [Figure not available: see fulltext.]

Novel method for preparing Prostaglandin derivatives

Provided is a novel method for preparing prostaglandin derivatives. The method is suitable for mass production by effectively manufacturing prostaglandin derivatives with high yield. The method comprises the following steps: (S-1) adding a first reducing agent to a prostaglandin intermediate compound represented by chemical formula II and manufacturing a compound represented by chemical formula III; (S-2) manufacturing a compound represented by chemical formula IV from the compound represented by chemical formula III in the presence of a base; (S-3) adding a second reducing agent to the compound represented by chemical formula IV and manufacturing a compound represented by chemical formula V; and (S-4) performing Wittig reaction of the compound represented by chemical formula V and a compound represented by chemical formula VI, and manufacturing a compound represented by chemical formula I.COPYRIGHT KIPO 2017

Processes for the preparation of isomer free prostaglandins

Novel processes for the preparation of a compound of Formula I-2 substantially free of the 5,6-trans isomer: wherein R2, R3 and R4 are as defined in the specification are provided. Novel intermediates for the preparations of isomer free Prostaglandins and derivatives thereof are also provided.